Compare · CGC vs NAGE
CGC vs NAGE
Side-by-side comparison of Canopy Growth Corporation (CGC) and Niagen Bioscience Inc. (NAGE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGC and NAGE operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CGC is the larger of the two at $2.86B, about 11.1x NAGE ($258.7M).
- Over the past year, CGC is down 27.9% and NAGE is down 67.7% - CGC leads by 39.8 points.
- CGC has been more active in the news (12 items in the past 4 weeks vs 8 for NAGE).
- CGC has more recent analyst coverage (19 ratings vs 1 for NAGE).
- Company
- Canopy Growth Corporation
- Niagen Bioscience Inc.
- Price
- $1.06-0.47%
- $3.25-0.61%
- Market cap
- $2.86B
- $258.7M
- 1M return
- +18.46%
- -1.52%
- 1Y return
- -27.89%
- -67.73%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 8
- Recent ratings
- 19
- 1
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Latest CGC
- Officer Gedeon Christelle sold $19,616 worth of shares (13,344 units at $1.47), decreasing direct ownership by 2% to 692,162 units (SEC Form 4) to cover taxes
- Officer Stewart Thomas Carlton sold $3,280 worth of shares (2,231 units at $1.47), decreasing direct ownership by 0.36% to 614,167 units (SEC Form 4) to satisfy withholding obligation
- SEC Form DEFA14A filed by Canopy Growth Corporation
- Canopy Growth Announces Mailing of Proxy Materials for 2026 Annual General and Special Meeting – Urges Shareholders to Vote Now
- SEC Form DEFA14A filed by Canopy Growth Corporation
- Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows
- SEC Form DEFA14A filed by Canopy Growth Corporation
- SEC Form DEF 14A filed by Canopy Growth Corporation
- Canopy Growth Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Canopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NAGE
- Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
- Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
- Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
- Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
- SEC Form 10-Q filed by Niagen Bioscience Inc.
- Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
- Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
- Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
- Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference